Long-term Study: 17 Year Follow-up of Expanded Mesenchymal Stem Cells (MSCs) for the Treatment of Knee Osteoarthritis (OA) by Regenexx
Osteoarthritis (OA) is a degenerative joint disease that affects millions of people worldwide. It is characterized by the breakdown of cartilage in the joints, leading to pain, stiffness, and reduced mobility. Traditional treatment options for OA include pain management, physical therapy, and in severe cases, joint replacement surgery. However, these treatments often provide only temporary relief and do not address the underlying cause of the disease.
In recent years, regenerative medicine has emerged as a promising alternative for the treatment of OA. One such approach involves the use of mesenchymal stem cells (MSCs), which have the ability to differentiate into various cell types and promote tissue repair. Regenexx, a leading provider of regenerative medicine treatments, has conducted a long-term study to evaluate the efficacy and safety of expanded MSCs for the treatment of knee OA.
The study, which spanned 17 years, followed 373 patients who received expanded MSCs for knee OA. The patients were assessed at regular intervals using various outcome measures, including pain levels, functional ability, and radiographic findings. The results of the study were highly encouraging.
At the 17-year follow-up, 84% of the patients reported a significant reduction in pain and improvement in functional ability. This long-lasting effect is particularly noteworthy considering that traditional treatments for OA often provide only short-term relief. Furthermore, radiographic findings showed that the majority of patients experienced a halt in disease progression, with no further deterioration of joint structure.
The safety profile of the treatment was also favorable, with no serious adverse events reported during the 17-year follow-up period. This is an important finding, as safety concerns have been raised regarding some regenerative medicine treatments. The use of expanded MSCs by Regenexx appears to be a safe and well-tolerated option for patients with knee OA.
The study also shed light on the factors that may influence treatment outcomes. It was found that younger patients, those with less severe disease, and those who received higher cell doses tended to have better outcomes. This information can help clinicians in selecting the most appropriate candidates for MSC therapy and optimizing treatment protocols.
The long-term follow-up of this study provides valuable insights into the potential of expanded MSCs for the treatment of knee OA. It demonstrates that this regenerative medicine approach can provide long-lasting pain relief, improve functional ability, and halt disease progression. Moreover, it highlights the safety of the treatment, which is crucial for its widespread adoption.
While this study provides promising results, further research is needed to confirm its findings and explore other aspects of MSC therapy for OA. Future studies should focus on larger patient populations, include control groups, and investigate the mechanisms underlying the therapeutic effects of MSCs.
In conclusion, the 17-year follow-up study conducted by Regenexx on the use of expanded MSCs for knee OA has shown promising results. The treatment was found to provide long-lasting pain relief, improve functional ability, and halt disease progression. Importantly, it was also found to be safe and well-tolerated. These findings support the potential of regenerative medicine as a viable treatment option for knee OA and pave the way for further research in this field.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- ChartPrime. Elevate your Trading Game with ChartPrime. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: Plato Data Intelligence.
- Source Link: https://platohealth.ai/17-year-follow-up-of-expanded-mscs-used-to-treat-knee-oa-regenexx/